AR035779A1 - Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos - Google Patents
Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismosInfo
- Publication number
- AR035779A1 AR035779A1 ARP020100382A ARP020100382A AR035779A1 AR 035779 A1 AR035779 A1 AR 035779A1 AR P020100382 A ARP020100382 A AR P020100382A AR P020100382 A ARP020100382 A AR P020100382A AR 035779 A1 AR035779 A1 AR 035779A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- fusion polypeptide
- fusion
- methods
- ibalfa
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 20
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 20
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 20
- 230000004927 fusion Effects 0.000 title abstract 9
- 108020004414 DNA Proteins 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102100023472 P-selectin Human genes 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 1
- 102100036537 von Willebrand factor Human genes 0.000 abstract 1
- 229960001134 von willebrand factor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
También provee una molécula de DNA que codifica dicho polipéptidode fusión, un vector que comprende dicho DNA, una célula que comprende dicho vector; un método para expresar el polipéptido de fusión; una composición farmacéutica que comprende el polipéptido de fusión; un método para inhibir la adherencia de una célula sanguínea y/ proteína a un tejido biológico mediante el uso del polipéptido de fusión, y a métodos para tratar trastornos vasculares con dicho polipéptido de fusión. Reivindicacion 1:Un polipéptido de fusión que comprende un primer polipéptido ligado operativamente a un segundo polipéptido, caracterizado porque el primer polipéptido comprende al menos una región de un polipéptido glicoproteína Ibalfa y el segundo polipéptido comprende al menos una región de un polipéptido de inmunoglobulina. Reivindicación 2:El polipéptido de fusión de acuerdo con la reivindicación 1, caracterizado porque dicho primer polipéptido incluye una porción extracelular de un polipéptido glicoproteína Ibalfa de membrana. Reivindicación 3: El polipéptido de fusión de la reivindicación 2, caracterizado porque dicho primer polipéptido se liga a uno o más de los polipéptidos seleccionados del grupo formado por un polipéptido integrina de leucocitos Mac-1, Factor von Willebrand, trombina y selectina P. Reivindicación 49: El método de la reivindicación 47, caracterizado porque dicho trastorno es enfermedad cardíaca isquemica, angina, infarto del miocardio agudo, apoplejía, trombosis venosa, aterosclerosis o trombosis arterial.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26683801P | 2001-02-06 | 2001-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035779A1 true AR035779A1 (es) | 2004-07-14 |
Family
ID=23016192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100382A AR035779A1 (es) | 2001-02-06 | 2002-02-05 | Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US6991796B2 (es) |
| EP (1) | EP1360292A2 (es) |
| KR (1) | KR20030074796A (es) |
| CN (1) | CN100523188C (es) |
| AR (1) | AR035779A1 (es) |
| AU (3) | AU2002240287B2 (es) |
| BR (1) | BR0207039A (es) |
| CA (1) | CA2437714A1 (es) |
| HU (1) | HUP0303167A2 (es) |
| IL (1) | IL157264A0 (es) |
| MX (1) | MXPA03007010A (es) |
| NO (1) | NO20033474L (es) |
| NZ (1) | NZ528037A (es) |
| PL (1) | PL373052A1 (es) |
| WO (1) | WO2002063003A2 (es) |
| ZA (1) | ZA200306229B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035779A1 (es) * | 2001-02-06 | 2004-07-14 | Genetics Inst Llc | Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos |
| JP2007537710A (ja) * | 2003-06-11 | 2007-12-27 | ワイス | 血小板糖タンパク質ＩＢα改変体融合ポリペプチドおよびその使用法 |
| JP2005073528A (ja) * | 2003-08-28 | 2005-03-24 | Genetics Inst Llc | 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物 |
| US8039588B2 (en) * | 2004-05-21 | 2011-10-18 | The Uab Research Foundation | Variable lymphocyte receptors |
| US20080015145A1 (en) | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
| DE102007031708A1 (de) | 2007-07-06 | 2009-01-08 | Dade Behring Marburg Gmbh | Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin |
| WO2010071934A1 (en) * | 2008-12-22 | 2010-07-01 | Baker Idi Heart And Diabetes Institute Holdings Limited | Modulation of platelet activation |
| CN102988983B (zh) * | 2011-09-09 | 2014-06-11 | 苏州苏大赛尔免疫生物技术有限公司 | 抗人血小板膜糖蛋白Ibα嵌合抗体药物组合物 |
| EP2794007A4 (en) * | 2011-12-23 | 2015-11-18 | Vasculogics Inc | COMPOSITIONS AND METHODS FOR TREATING THROMBOSES AND EXTENDING THE LIFE OF THE STORED THROMBOCYTES |
| KR102139393B1 (ko) | 2012-06-26 | 2020-07-29 | 지이 헬스케어 에이에스 | 기체 미세기포를 포함하는 조성물의 제조 |
| EP2919013B1 (de) | 2014-03-11 | 2016-11-02 | Siemens Healthcare Diagnostics Products GmbH | Verfahren zur Detektion von Modulatoren der GPIb-Thrombin-Interaktion |
| CN107340225B (zh) * | 2017-07-13 | 2019-07-05 | 徐州医科大学 | 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法 |
| UY38092A (es) | 2018-02-20 | 2019-05-31 | Solicitante Grifols Diagnostic Solutions Inc | COMPOSICIÓN QUE COMPRENDE UNA PROTEÍNA RECOMBINANTE RECEPTORA GPIba |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| IL88308A0 (en) * | 1987-11-17 | 1989-06-30 | Scripps Clinic Res | Peptides that block the binding of von willebrand factor |
| US5340727A (en) * | 1987-11-17 | 1994-08-23 | The Scripps Research Institute | GPIbα fragments and recombinant DNA expression vectors |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5317097A (en) * | 1991-10-07 | 1994-05-31 | The Research Foundation Of State University Of New York | Mutations in the gene encoding the α chain on platelet glycoprotein IB |
| US6277975B1 (en) * | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
| US5516964A (en) * | 1994-01-21 | 1996-05-14 | Sun Company, Inc. (R&M) | Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal |
| JP3735921B2 (ja) * | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | ＧＰＩｂ・脂質複合体およびその用途 |
| EP1068241B1 (en) * | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6878811B1 (en) * | 1998-04-23 | 2005-04-12 | Ajinomoto Co., Inc. | Substance with antithrombotic activity and method for detecting glycokallidin |
| AR035779A1 (es) * | 2001-02-06 | 2004-07-14 | Genetics Inst Llc | Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos |
| US6878881B1 (en) * | 2004-09-08 | 2005-04-12 | Stephen K. Henry | Modular cable protector assembly |
-
2002
- 2002-02-05 AR ARP020100382A patent/AR035779A1/es not_active Application Discontinuation
- 2002-02-06 EP EP02706182A patent/EP1360292A2/en not_active Withdrawn
- 2002-02-06 KR KR10-2003-7010381A patent/KR20030074796A/ko not_active Application Discontinuation
- 2002-02-06 US US10/068,426 patent/US6991796B2/en not_active Expired - Fee Related
- 2002-02-06 CA CA002437714A patent/CA2437714A1/en not_active Abandoned
- 2002-02-06 AU AU2002240287A patent/AU2002240287B2/en not_active Ceased
- 2002-02-06 PL PL02373052A patent/PL373052A1/xx unknown
- 2002-02-06 WO PCT/US2002/003549 patent/WO2002063003A2/en active Application Filing
- 2002-02-06 CN CNB028061489A patent/CN100523188C/zh not_active Expired - Fee Related
- 2002-02-06 NZ NZ528037A patent/NZ528037A/en unknown
- 2002-02-06 HU HU0303167A patent/HUP0303167A2/hu unknown
- 2002-02-06 MX MXPA03007010A patent/MXPA03007010A/es active IP Right Grant
- 2002-02-06 IL IL15726402A patent/IL157264A0/xx unknown
- 2002-02-06 BR BR0207039-1A patent/BR0207039A/pt not_active IP Right Cessation
-
2003
- 2003-03-06 US US10/382,758 patent/US7049128B2/en not_active Expired - Fee Related
- 2003-08-05 NO NO20033474A patent/NO20033474L/no unknown
- 2003-08-12 ZA ZA200306229A patent/ZA200306229B/en unknown
-
2005
- 2005-10-24 US US11/257,581 patent/US20060093614A1/en not_active Abandoned
- 2005-10-24 US US11/257,579 patent/US20060140935A1/en not_active Abandoned
-
2006
- 2006-11-24 AU AU2006241373A patent/AU2006241373A1/en not_active Abandoned
-
2008
- 2008-10-21 US US12/254,940 patent/US20090148427A1/en not_active Abandoned
-
2011
- 2011-03-03 AU AU2011200943A patent/AU2011200943A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0303167A2 (hu) | 2003-12-29 |
| KR20030074796A (ko) | 2003-09-19 |
| CN1553955A (zh) | 2004-12-08 |
| US20060140935A1 (en) | 2006-06-29 |
| NO20033474L (no) | 2003-10-02 |
| PL373052A1 (en) | 2005-08-08 |
| NZ528037A (en) | 2006-08-31 |
| US7049128B2 (en) | 2006-05-23 |
| MXPA03007010A (es) | 2004-07-08 |
| CN100523188C (zh) | 2009-08-05 |
| AU2011200943A1 (en) | 2011-03-24 |
| AU2006241373A1 (en) | 2006-12-14 |
| AU2002240287B2 (en) | 2006-08-24 |
| US20030232047A1 (en) | 2003-12-18 |
| NO20033474D0 (no) | 2003-08-05 |
| US20030091576A1 (en) | 2003-05-15 |
| ZA200306229B (en) | 2005-05-26 |
| EP1360292A2 (en) | 2003-11-12 |
| WO2002063003A3 (en) | 2003-05-15 |
| BR0207039A (pt) | 2005-05-03 |
| IL157264A0 (en) | 2004-02-19 |
| CA2437714A1 (en) | 2002-08-15 |
| WO2002063003A2 (en) | 2002-08-15 |
| US20090148427A1 (en) | 2009-06-11 |
| US20060093614A1 (en) | 2006-05-04 |
| US6991796B2 (en) | 2006-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035779A1 (es) | Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos | |
| D'Souza et al. | Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif | |
| Thiagarajan et al. | Exposure of binding sites for vitronectin on platelets following stimulation. | |
| Nishimura et al. | Integrin alpha v beta 8. Interaction with vitronectin and functional divergence of the beta 8 cytoplasmic domain. | |
| Savage et al. | Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site (s) on platelet glycoprotein IIb. IIIa complex inhibits receptor function. | |
| Marcinkiewicz et al. | EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner | |
| Dejana et al. | Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. | |
| Gonzales et al. | Structure and function of a vimentin-associated matrix adhesion in endothelial cells | |
| AR119235A1 (es) | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO | |
| Oldberg et al. | Identification of a bone sialoprotein receptor in osteosarcoma cells. | |
| Caiado et al. | Endothelial progenitor cells and integrins: adhesive needs | |
| Ni et al. | Control of thrombus embolization and fibronectin internalization by integrin αIIbβ3 engagement of the fibrinogen γ chain | |
| Weiss et al. | Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. | |
| Marcantonio et al. | Antibodies to the conserved cytoplasmic domain of the integrin beta 1 subunit react with proteins in vertebrates, invertebrates, and fungi. | |
| Kunicki | Platelet membrane glycoproteins and their function: an overview | |
| Nurden | Platelet membrane glycoproteins: a historical review | |
| ES2147558T3 (es) | Nuevos polipeptidos para promover la fijacion celular. | |
| Odrljin et al. | Heparin-binding domain of fibrin mediates its binding to endothelial cells | |
| NO20000934D0 (no) | Adipocyttspesifikke proteinhomologer | |
| DK0686161T3 (da) | Alfa-underenhed af humane beta2-integriner | |
| Nishiya et al. | Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ibα under flow conditions: specific synergy of receptor–ligand interactions | |
| Nakamura et al. | Construction of multi-functional extracellular matrix proteins that promote tube formation of endothelial cells | |
| ATE179718T1 (de) | Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen | |
| NO20000215D0 (no) | Adipocyttspesifikke proteinhomologer | |
| MARCINKIEWICZ et al. | Immunological characterization of eristostatin and echistatin binding sites on αIIb β3 and αVβ3 integrins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |